A double blind, placebo controlled Phase 2 dose ranging study of the effects of ARA 290 on corneal nerve fiber density and neuropathic symptoms of patients with sarcoidosis.

Trial Profile

A double blind, placebo controlled Phase 2 dose ranging study of the effects of ARA 290 on corneal nerve fiber density and neuropathic symptoms of patients with sarcoidosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 May 2017

At a glance

  • Drugs Cibinetide (Primary)
  • Indications Neuropathic pain; Sarcoidosis
  • Focus Therapeutic Use
  • Acronyms DOSARA
  • Sponsors Araim Pharmaceuticals
  • Most Recent Events

    • 08 May 2017 Results published in an Araim Pharmaceuticals media release.
    • 08 May 2017 Primary endpoint (Change in Corneal Nerve Fiber Area) has been met, according to an Araim Pharmaceuticals media release.
    • 05 Jul 2016 According to the Araim Pharmaceuticals media release, the US Food and Drug Administration (FDA) and the EU has granted Orphan Drug Designation to Cibinetide (ARA 290) for the treatment of sarcoidosis. Also, it has received a Fast Track designations from USFDA for the treatment of neuropathic pain in patients with sarcoidosis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top